Evolution and characteristics of the use of valproate in women of childbearing age with bipolar disorder: Results from the FACE-BD cohort.
Journal of Affective Disorders. 2020-11-01; 276: 963-969
DOI: 10.1016/j.jad.2020.07.078
Lire sur PubMed
1. J Affect Disord. 2020 Nov 1;276:963-969. doi: 10.1016/j.jad.2020.07.078. Epub
2020 Jul 21.
Evolution and characteristics of the use of valproate in women of childbearing
age with bipolar disorder: Results from the FACE-BD cohort.
Samalin L(1), Godin O(2), Olié E(3), Etain B(4), Henry C(5), Pelletier A(6),
Poinso F(7), Encely L(7), Mazer N(8), Roux P(9), Loftus J(10), Gard S(10),
Bennabi D(11), Polosan M(12), Schwitzer T(13), Aubin V(10), Schwan R(13),
Passerieux C(9), Bougerol T(12), Dubertret C(8), Aouizerate B(14), Haffen E(11),
Courtet P(3), Bellivier F(4), Leboyer M(6); FACE-BD collaborators; Llorca
PM(15), Belzeaux R(16).
Author information:
(1)Fondation Fondamental, Créteil, France; Department of Psychiatry, CHU
Clermont-Ferrand, University of Clermont Auvergne, EA 7280, Clermont-Ferrand,
France. Electronic address: .
(2)Fondation Fondamental, Créteil, France; INSERM U955, Équipe de Psychiatrie
Translationnelle, Université Paris-Est Créteil, DHU Pe-PSY, Pôle de Psychiatrie
des Hôpitaux Universitaires H Mondor, Créteil, France.
(3)Fondation Fondamental, Créteil, France; Department of Emergency Psychiatry
and Acute Care, CHU de Montpellier, PSNREC, University Montpellier, INSERM,
Montpellier, France.
(4)Fondation Fondamental, Créteil, France; AP-HP, GH Saint-Louis – Lariboisière
– Fernand Widal, Pôle Neurosciences Tête et Cou, Département de Psychiatrie et
de Médecine Addictologique, INSERM UMRS 1144, Université de Paris, Paris,
France.
(5)Department of Psychiatry, Service Hospitalo-Universitaire, GHU Paris
Psychiatrie and Neurosciences, Université Descartes, Paris, France.
(6)Fondation Fondamental, Créteil, France; AP-HP, DMU IMPACT, Psychiatry and
Addictology of Mondor University Hospital, University Paris-Est-Créteil,
Créteil, France.
(7)Pôle de Psychiatrie, APHM, Marseille, France; INT-UMR7289, CNRS Aix-Marseille
Université, Marseille, France.
(8)Fondation Fondamental, Créteil, France; AP-HP, Groupe Hospitalo-universitaire
AP-HP Nord, DMU ESPRIT, Service de Psychiatrie et Addictologie, Hôpital Louis
Mourier, Colombes, Inserm U1266, Faculté de Médecine, Université de Paris,
France.
(9)Fondation Fondamental, Créteil, France; Centre Hospitalier de Versailles,
Service Universitaire de psychiatrie d’adulte et d’addictologie, Le Chesnay, EA
4047 HANDIReSP, UFR des Sciences de la Santé Simone Veil, Université Versailles
Saint-Quentin-en-Yvelines, Equipe « PsyDev », CESP, Université Paris-Saclay,
Inserm, 94807 Villejuif, France.
(10)Fondation Fondamental, Créteil, France; Department of Psychiatry,
Princess-Grace Hospital, Monaco, Monaco.
(11)Fondation Fondamental, Créteil, France; Department of Clinical Psychiatry,
CIC-1431 INSERM, CHU de Besançon, EA481 Neurosciences, University Bourgogne
Franche-Comté, France.
(12)Fondation Fondamental, Créteil, France; CHU Grenoble Alpes, Grenoble
Institut Neurosciences, Inserm, U1216, University of Grenoble Alpes, Grenoble,
France.
(13)Fondation Fondamental, Créteil, France; Centre Psychothérapique de Nancy,
Pôle Hospitalo-universitaire de Psychiatrie d’Adultes du Grand Nancy, Laxou
F-54520, France.
(14)Fondation Fondamental, Créteil, France; Department of Clinical and Academic
Psychiatry, Charles-Perrens Hospital, Bordeaux, France; NutriNeuro, UMR INRA
1286, University of Bordeaux, Bordeaux, France.
(15)Fondation Fondamental, Créteil, France; Department of Psychiatry, CHU
Clermont-Ferrand, University of Clermont Auvergne, EA 7280, Clermont-Ferrand,
France.
(16)Fondation Fondamental, Créteil, France; Pôle de Psychiatrie, APHM,
Marseille, France; INT-UMR7289, CNRS Aix-Marseille Université, Marseille,
France.
BACKGROUND: Valproate is associated with teratogenic and neurodevelopmental
effects. Several agencies have restricted the conditions of its prescription in
bipolar disorders (BD). We aimed to assess the evolution of valproate
prescription and the clinical profile of BD women of childbearing age receiving
valproate.
METHODS: Based on a large national cohort, we included all BD women 16-50 years
old. Sociodemographic, clinical and pharmacological data were recorded. Logistic
regression analyses were used to describe variables associated with valproate
prescription.
RESULTS: Of the 1018 included women 16-50 years old, 26.9% were treated with
valproate with a mean daily dosage of 968 mg. The prevalence of BD women using
valproate was 32.6% before May 2015 and 17.3% after May 2015 (p